BUDESONIDE; FORMOTEROL FUMARATE; GLYCOPYRROLATE - Generic Drug Details

What are the generic drug sources for budesonide; formoterol fumarate; glycopyrrolate and what is the scope of freedom to operate?

Budesonide; formoterol fumarate; glycopyrrolate is the generic ingredient in one branded drug marketed by Astrazeneca Ab and is included in one NDA. There are nine patents protecting this compound. Additional information is available in the individual branded drug profile pages.

One supplier is listed for this compound.

Summary for BUDESONIDE; FORMOTEROL FUMARATE; GLYCOPYRROLATE

International Patents:	219
US Patents:	9
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for BUDESONIDE; FORMOTEROL FUMARATE; GLYCOPYRROLATE
DailyMed Link:	BUDESONIDE; FORMOTEROL FUMARATE; GLYCOPYRROLATE at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for BUDESONIDE; FORMOTEROL FUMARATE; GLYCOPYRROLATE

Constraining patent/regulatory exclusivity:

NEW STRENGTH

Dosage:

AEROSOL, METERED;INHALATION

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for BUDESONIDE; FORMOTEROL FUMARATE; GLYCOPYRROLATE

Drug Class	Anticholinergic Cholinergic Muscarinic Antagonist Corticosteroid beta2-Adrenergic Agonist
Mechanism of Action	Adrenergic beta2-Agonists Cholinergic Antagonists Cholinergic Muscarinic Antagonists Corticosteroid Hormone Receptor Agonists

Anatomical Therapeutic Chemical (ATC) Classes for BUDESONIDE; FORMOTEROL FUMARATE; GLYCOPYRROLATE

A07EA	Corticosteroids acting locally
A07E	INTESTINAL ANTIINFLAMMATORY AGENTS
A07	ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS
A	Alimentary tract and metabolism

D07AB	Corticosteroids, moderately potent (group II)
D07A	CORTICOSTEROIDS, PLAIN
D07	CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS
D	Dermatologicals

D07AC	Corticosteroids, potent (group III)
D07A	CORTICOSTEROIDS, PLAIN
D07	CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS
D	Dermatologicals

R01AD	Corticosteroids
R01A	DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE
R01	NASAL PREPARATIONS
R	Respiratory system

R03AC	Selective beta-2-adrenoreceptor agonists
R03A	ADRENERGICS, INHALANTS
R03	DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
R	Respiratory system

R03BA	Glucocorticoids
R03B	OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS
R03	DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
R	Respiratory system

R03CC	Selective beta-2-adrenoreceptor agonists
R03C	ADRENERGICS FOR SYSTEMIC USE
R03	DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
R	Respiratory system

S01BA	Corticosteroids, plain
S01B	ANTIINFLAMMATORY AGENTS
S01	OPHTHALMOLOGICALS
S	Sensory organs

US Patents and Regulatory Information for BUDESONIDE; FORMOTEROL FUMARATE; GLYCOPYRROLATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astrazeneca Ab	BREZTRI AEROSPHERE	budesonide; formoterol fumarate; glycopyrrolate	AEROSOL, METERED;INHALATION	212122-002	Apr 27, 2026		RX	Yes	Yes	8,324,266
Astrazeneca Ab	BREZTRI AEROSPHERE	budesonide; formoterol fumarate; glycopyrrolate	AEROSOL, METERED;INHALATION	212122-001	Jul 23, 2020		RX	Yes	Yes	11,833,292		Y
Astrazeneca Ab	BREZTRI AEROSPHERE	budesonide; formoterol fumarate; glycopyrrolate	AEROSOL, METERED;INHALATION	212122-002	Apr 27, 2026		RX	Yes	Yes	11,833,292		Y
Astrazeneca Ab	BREZTRI AEROSPHERE	budesonide; formoterol fumarate; glycopyrrolate	AEROSOL, METERED;INHALATION	212122-002	Apr 27, 2026		RX	Yes	Yes	9,415,009
Astrazeneca Ab	BREZTRI AEROSPHERE	budesonide; formoterol fumarate; glycopyrrolate	AEROSOL, METERED;INHALATION	212122-001	Jul 23, 2020		RX	Yes	Yes	8,703,806

International Patents for BUDESONIDE; FORMOTEROL FUMARATE; GLYCOPYRROLATE

Country	Patent Number	Title	Estimated Expiration
Argentina	076621
Argentina	076806
Argentina	076807
Argentina	121758
Argentina	122477

Supplementary Protection Certificates for BUDESONIDE; FORMOTEROL FUMARATE; GLYCOPYRROLATE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2435025	C201930043	Spain		PRODUCT NAME: UNA COMBINACION DE GLICOPIRROLATO (INCLUYENDO CUALQUIERA DE SUS SALES, ESTERES O ENANTIOMEROS FARMACEUTICAMENTE ACEPTABLES) Y FORMOTEROL (INCLUYENDO CUALQUIERA DE SUS SALES, ESTERES O ENANTIOMEROS FARMACEUTICAMENTE ACEPTABLES).; NATIONAL AUTHORISATION NUMBER: EU/1/18/1339; DATE OF AUTHORISATION: 20181218; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/18/1339; DATE OF FIRST AUTHORISATION IN EEA: 20181218
2435025	C20190028 00438	Estonia		PRODUCT NAME: GLUEKOPUERROONIUMBROMIID/FORMOTEROOL;REG NO/DATE: EU/1/18/1339 20.12.2018
2435024	202140009	Slovenia		PRODUCT NAME: COMBINATION OF FORMOTEROL (INCLUDING ANY PHARMACEUTICALLY ACCEPTABLE SALTS, ESTERS, SOLVATES OR ENANTIOMERS THEREOF), GLYCOPYRROLATE (INCLUDING ANY PHARMACEUTICALLY ACCEPTABLE SALTS, ESTERS, SOLVATES OR ENANTIOMERS THEREOF) AND BUDESONIDE (INCLUDING ANY PHARMACEUTICALLY ACCEPTABLE SALTS, ESTERS, SOLVATES OR ENANTIOMERS THEREOF); NATIONAL AUTHORISATION NUMBER: EU/1/20/1498; DATE OF NATIONAL AUTHORISATION: 20201209; AUTHORITY FOR NATIONAL AUTHORISATION: EU
2435025	201940030	Slovenia		PRODUCT NAME: COMBINATION OF GLYCOPYRROLATE (INCLUDING ANY PHARMACEUTICALLY ACCEPTABLE SALTS, ESTERS, ENANTIOMERES) AND FORMOTEROLE (INCLUDING ANY PHARMACEUTICALLY ACCEPTABLE SALTS, ESTERS, ENANTIOMERES); NATIONAL AUTHORISATION NUMBER: EU/1/18/1339; DATE OF NATIONAL AUTHORISATION: 20181218; AUTHORITY FOR NATIONAL AUTHORISATION: EU
2435025	36/2019	Austria		PRODUCT NAME: GLYCOPYRRONIUMBROMID / FORMOTEROL; REGISTRATION NO/DATE: EU/1/18/1339 (MITTEILUNG) 20181220

Last updated: April 26, 2026

Market dynamics and financial trajectory for budesonide; formoterol fumarate; glycopyrrolate

What is the product and how does it sit in the respiratory market?

Budesonide; formoterol fumarate; glycopyrrolate is an inhaled, fixed-dose triple therapy for chronic obstructive pulmonary disease (COPD). It pairs:

• Budesonide (inhaled corticosteroid)
• Formoterol fumarate (long-acting beta2 agonist, LABA)
• Glycopyrrolate (long-acting muscarinic antagonist, LAMA)

This places the product in the COPD triple-therapy segment where payers and clinicians increasingly favor once or twice daily combinations that reduce exacerbations and avoid systemic steroid burden. Market structure is dominated by multiple competing triple inhalers, with pricing and access driven by formulary position, step-therapy rules, and biosimilar and generic dynamics in adjacent therapy classes.

Where does the revenue come from and what demand signals matter?

Financial trajectory in COPD inhalers is driven by three levers:

1. Exacerbation reduction value: COPD triple therapy is typically positioned for higher-risk patients (frequent exacerbators, persistent symptoms on dual therapy).
2. Channel access: uptake hinges on formulary inclusions and the breadth of net price discounts versus list price.
3. Share shift dynamics: triple therapy tends to win share from ICS/LABA or LAMA/LABA when payers remove step edits for “high exacerbator” criteria.

The demand baseline is supported by the size and chronic nature of COPD, but the slope of growth depends on competitive switching and contract pricing.

What do the key competitive dynamics look like (class and peer set)?

The budesonide/formoterol/glycopyrrolate combination competes in a crowded COPD triple landscape that includes:

• Fixed-dose triple inhalers (other ICS/LABA/LAMA combinations)
• Dual-therapy escalation strategies where payers allow triple only after documented dual failure
• Device- and dosing-frequency-led switching, with emphasis on inhaler technique and refill persistence

In this segment, the near-term market outcome is less about disease incidence and more about:

• Formulary stability
• Contracting cadence and gross-to-net erosion
• Therapy line conversion rate from dual to triple

How does the drug’s financial trajectory typically evolve for triple inhalers?

For COPD fixed-dose triple inhalers, the usual financial pattern is:

• Launch-to-peak ramp: share gains in newly eligible patients and those switching from dual therapy
• Mid-cycle maturity: growth moderates as penetration saturates in treated populations
• Late-cycle pressure: margin compresses with stronger contracting, competitive entrants, or higher generic pressure in adjacent classes (not always directly on triple inhalers but via payer pressure on respiratory spend)

For investors and R&D planners, the differentiator is whether the product is gaining share faster than peers or losing share due to formulary exits, unfavorable contract terms, or device competition.

What is the status of exclusivity and how does it shape long-term valuation?

A triple inhaler’s valuation is heavily shaped by its IP runway across:

• Composition of matter
• Method-of-use and formulation
• Device and delivery system claims (where applicable)
• Regulatory exclusivities and patent “thickets” by geography

As a rule in inhaled respiratory, long patent estates can delay full generic entry, but biosimilar-like substitution is not the relevant mechanism. The relevant substitution is generic or authorized generics of the individual molecules and fixed-dose combinations, where feasible, depending on patent barriers.

Without a complete, jurisdiction-by-jurisdiction patent map for budesonide/formoterol/glycopyrrolate, the only defensible statement is that the long-term financial trajectory is IP-dependent and can shift abruptly around the first true generic or authorized-generic threat. Patent litigation outcomes and settlement terms often dominate the market outcome more than underlying clinical demand.

What is the likely revenue path across geographies and payer systems?

Revenue and margin behavior differ by market:

• US: high contracting intensity and pharmacy benefit manager (PBM) influence. Net price erosion can be fast during maturity.
• EU5 and UK: reimbursement frameworks vary, with tighter health technology assessment (HTA) and formulary control. Volume growth can be slower but pricing can be more stable once accepted.
• Emerging markets: higher distribution leverage matters, but procurement cycles and tender rules can produce lumpy sales.

Budesonide/formoterol/glycopyrrolate’s financial trajectory is expected to follow the cadence of:

• payer formulary decisions,
• regional tender renewals,
• and competitive bid cycles against peer triple inhalers.

How do gross-to-net and margin typically behave in COPD triple therapy?

Inhaled COPD revenue usually experiences:

• Net price pressure as competitors intensify contracting and payers shift to preferred products
• Promotional intensity shifts toward channel pull (prescriber education and copay support where allowed) rather than pure list price incentives
• Cost-of-goods stability relative to API exposure, but device and inhaler manufacturing overhead can still constrain margins if volumes or mix change

For a business decision, the key is whether the product maintains net share growth without proportionate increases in discounting.

What financial metrics should be tracked to validate trajectory?

For budesonide/formoterol/glycopyrrolate, the actionable KPIs are:

• US prescription growth vs. COPD triple peer set
• Net sales growth vs. unit growth (net price changes)
• Ex-factory vs. sell-through divergence (channel inventory risk)
• Exacerbation-related patient segmentation (share skew to higher-risk cohorts, where payers accept triple)
• Contract coverage duration (formulary depth and switching risk)

These indicators determine whether the product is in a share-gain phase or a contracting-induced slowdown phase.

---

Market sizing context and segment dynamics (how triple therapy wins)

Why triple therapy dynamics matter for sales direction

COPD triple therapy is pulled by:

• Clinical guideline evolution that escalates to triple therapy for higher symptom burden or exacerbator phenotype.
• Payer and PBM preferences that treat triple as the “preferred add-on” when dual therapy fails, under documented criteria.

The result is that market dynamics for triple inhalers are not linear with patient numbers. They follow:

• conversion from dual to triple,
• adherence (persistence and refills),
• and formulary stickiness.

What causes switching to accelerate or stall?

Switching accelerates when:

• the product is preferred on formularies for exacerbator criteria,
• device usability supports correct inhalation technique,
• and copay dynamics do not block patient access.

Switching stalls when:

• competitors undercut net price via contracts,
• payers reintroduce step edits,
• or device performance differences reduce adherence.

---

Competitive benchmarking framework (operational view)

How to benchmark budesonide/formoterol/glycopyrrolate against peers

A practical approach is to compare it on:

• Formulary share: percentage of lives covered under preferred or non-restricted status
• Contracting aggressiveness: how quickly net price declines relative to unit growth
• Device-driven persistence: continuation rates at 3, 6, and 12 months
• Exacerbation-risk targeting: uptake in frequent-exacerbator segments

This determines whether the product’s financial trajectory is “volume-led” or “price-led,” which affects long-term margin durability.

---

Key Takeaways

1. Budesonide; formoterol fumarate; glycopyrrolate is a fixed-dose ICS/LABA/LAMA triple therapy for COPD, competing in a high-contracting-intensity class where formulary access drives sales more than incidence growth.
2. The product’s financial trajectory is governed by share conversion from dual therapies, net price erosion, and persistence/adherence rather than by raw patient prevalence alone.
3. Valuation and long-term outlook are IP runway- and settlement-dependent, with generic or authorized-generic threats typically reshaping the market quickly once barriers fall.
4. The most decision-relevant KPIs are US prescription/unit trends, net sales vs. units, sell-through vs. ex-factory, segment uptake, and contract coverage duration.

---

FAQs

1) What market segment does budesonide/formoterol/glycopyrrolate target?

It targets COPD patients who require triple inhaled therapy (ICS/LABA/LAMA) after inadequate control on dual therapy or for higher-risk phenotypes.

2) What typically drives revenue growth in triple COPD inhalers?

Revenue growth typically comes from increased prescription volume due to formulary placement and conversion from dual to triple, rather than from unit pricing alone.

3) What typically pressures margins in this class?

Margins face pressure from gross-to-net discounting, preferred formulary contracting, and competitive bidding that drives down net price even when units hold.

4) Does generic erosion happen through individual molecule substitution or fixed-dose competition?

The main substitution risk usually comes from fixed-dose combination generic entry when patent barriers allow, rather than from independent substitution in practice.

5) What operational metrics signal whether trajectory is improving or weakening?

Track units vs net sales, persistence, sell-through vs channel inventory, and coverage depth (preferred vs restricted) against the peer set.

---

References

[1] U.S. National Library of Medicine. “Budesonide; Formoterol fumarate; Glycopyrrolate” (product information and pharmacology references on Drugs@FDA and related records). https://www.nlm.nih.gov/medlineplus/